Sentinels / Actor desk
Chinese National Medical Products Administration
organization · Registry status: unverified
a2d6d85a-050b-5d4f-abb7-0f04d0ca02bf
Evidence, not intent.
Public-source event mentions and stored signals. Adjacency does not establish causation, coordination, or an actor's position.
No claim of complete coverage or live monitoring.
Observation window
UTC dates, inclusive · maximum 90 days. Applies to events and anomalies only.
Recent observations / timeline
The source record
148 distinct events shown, newest first. Headlines may be generated summaries; inspect the source before repeating a claim.
Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product
Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding Product Commercialization Footprint
Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding Product Commercialization Footprint
World Traditional Medicine Conference 2026 Backs Research, AI and Plant Conservation - ChinaTechNews.com
Traditional Medicine Conference 2026 Delivers Global Health Milestones
Nuance Pharma Announces First Patient Dosed in REACH Phase III Trial of STG320 (Actair®) in China
Altruist Biologics' Integrated CMC Platform Supports NMPA Acceptance of NDA for Localized Manufacturing of Multinational Client's Biologic
CNIPA upholds validity of pharmaceutical use patent for crisaborole
United Imaging Healthcare Reports 19.43% Revenue Growth in Q1-Q3 2026, with International Revenue Up 50.30%
United Imaging Healthcare Reports 19.43% Revenue Growth in Q1-Q3 2026, with International Revenue Up 50.30%
HUTCHMED's Sovleplenib Receives U.S. FDA Orphan Drug Designation For ITP
Junshi's Toripalimab Subcutaneous Injection Application Accepted In China For Bladder Cancer
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Bayer's Asundexian Becomes First Factor XIa Inhibitor Approved In China For Stroke Prevention
morningstar.com: Christine Roth, Adria Calatayud, Adria Calatayud (wb 1331 health technologies, wb 1331 health technologies)
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO – Thailand Business News
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Kelun-Biotech Reports Longer Progression-Free Survival in Phase 3 Lung Trial | EconoTimes
Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event - Australian Bloggers
Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026 – Thailand Business News
Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026
Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026
philippinetimes.com: Liu Zhanyan, Qin Xingjiong, Qin Xingjiong (tax fncact tenant, env oil)
19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event – Thailand Business News
singaporestar.com: Qin Xingjiong, Qin Xingjiong, Qin Xingjiong (soc innovation, wb 1350 pharmaceuticals)
19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event
19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event
19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event
19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event
19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
Novartis Pharma AG: Kisqali shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
Galderma's Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Galderma's Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Galderma's Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Galderma's Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Galderma's Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Galderma's Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Galderma's Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Galderma's Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea
Galderma's Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea
Galderma's Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Galderma's Relfydess (relabotulinumtoxinA) Receives Approval in China for Frown Lines
beijingbulletin.com: Zhao Ruiqi, Yu Guoyong, Huangdi Neijing (general health, general health)
Young Chinese infuse millennia-old herbal wisdom into daily life
Feature: Young Chinese infuse millennia-old herbal wisdom into daily life
BCI training could help restore fine motor skills
Young Chinese infuse millennia-old herbal wisdom into daily life
Young Chinese infuse millennia-old herbal wisdom into daily life
Takeda’s ORZEYFUL Launches Simultaneously in Japan, China for Narcolepsy Type 1
Lisaftoclax Plus Acalabrutinib Received Breakthrough Therapy Designation in China for Treatment-Naive CLL/SLL | OncLive
Feature: Young Chinese infuse millennia-old herbal wisdom into daily life
Health minister wraps up China visit with new cooperation agenda
Health minister wraps up China visit with new cooperation agenda
Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value
Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value
Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value
Sphere 3D (NASDAQ:ANY) versus Advanced Biomed (NASDAQ:ADVB) Critical Survey
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026
Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026 - Thailand Business News
Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026
Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026
Shoreline Medical Administration, CHUM Health and Cellution Biologics Launch Elite Graft Program for Advanced Wound Care
InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
China Approves Foresee's CAMCEVI For Advanced Prostate Cancer
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension | HCPLive
Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform
Akeso, Inc.: First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer - Thailand Business News
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform
China expands intl cooperation in TCM to benefit more people globally
China expands intl cooperation in TCM to benefit more people globally
China expands intl cooperation in TCM to benefit more people globally
Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform
acnnewswire.com: Yifang Wu, Brandon Coder, Lakshmi Srinivasan (tax disease diseases, tax disease diseases)
Everest Medicines Limited: Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform
Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform
Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
Biopharma building innovation ecosystem
Biopharma building innovation ecosystem
Biopharma building innovation ecosystem
Nouryon cleared by regulators to supply a plant-based, water-soluble pharmaceutical ingredient in China's expanding drug manufacturing market
Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® subject to certain conditions, Advancing the Global Development and Commercialization of a Non-Surgical Treatment for Cervical Precancerous Lesions in Europe - Thailand Business News
Global investors target select opportunities in China’s maturing PE market
Asia-Pacific Roundup: TGA starts 5-year transition to new Australian medicine labeling standards
Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localiz
Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R)
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Proexpo Communications Limited: Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
Signals to inspect
Anomalies
Latest 10 in the selected window (up to 10). Detector output, not verified conclusions.
New connection: 8 previously unseen co-actor(s) detected (known network: 28)
Tone shift: score 10.5 deviates 2.2σ from baseline mean 2.4 (stddev 3.63)
New connection: 1 previously unseen co-actor(s) detected (known network: 27)
Volume spike: 2 events in window (2.0x baseline of 1.0 expected)
New connection: 10 previously unseen co-actor(s) detected (known network: 17)
Volume spike: 2 events in window (2.0x baseline of 1.0 expected)
Tone shift: score 9.6 deviates 2.3σ from baseline mean 2.0 (stddev 3.25)
Tone shift: score 9.6 deviates 2.8σ from baseline mean 1.6 (stddev 2.84)
New connection: 11 previously unseen co-actor(s) detected (known network: 12)
Narrative context
Unresolved threads
Latest 20 at most, across all dates. Stored narratives require human review.
Stored connections
Relationships
Up to 50 records ordered by evidence count, across all dates. Co-mentions indicate association in source material, not affiliation or coordination.
- Chinese National Medical Products Administration→ co mention →United States Senate237 evidence records
- Chinese National Medical Products Administration→ co mention →A Xinhua News Agency Production227 evidence records
- Drug Enforcement Administration→ co mention →Chinese National Medical Products Administration226 evidence records
- Chinese National Medical Products Administration→ co mention →Xinhua167 evidence records
- Apple Daily→ co mention →Chinese National Medical Products Administration161 evidence records
- Renfeng Guo→ co mention →Chinese National Medical Products Administration151 evidence records
- Wang Zhenjun→ co mention →Chinese National Medical Products Administration151 evidence records
- Shanxi Tongzhou→ co mention →Chinese National Medical Products Administration151 evidence records
- Terms Of Service→ co mention →Chinese National Medical Products Administration150 evidence records
- Xinhua Zhang Fengguo→ co mention →Chinese National Medical Products Administration123 evidence records
- Chinese National Medical Products Administration→ co mention →Ricardo Castillo122 evidence records
- Chinese National Medical Products Administration→ co mention →Securities and Exchange Commission87 evidence records
- Stock Exchange Of Hong Kong Limited Hkex→ co mention →Chinese National Medical Products Administration85 evidence records
- Sun Pharmaceuticals On→ co mention →Chinese National Medical Products Administration77 evidence records
- Nasdaq→ co mention →Chinese National Medical Products Administration73 evidence records
- Punjab National Health Mission→ co mention →Chinese National Medical Products Administration70 evidence records
- Linkedin→ co mention →Chinese National Medical Products Administration66 evidence records
- Chinese National Medical Products Administration→ co mention →Yong Tai Wang63 evidence records
- Chinese National Medical Products Administration→ co mention →National Reimbursement Drug List Of China63 evidence records
- Prnewswire Telix Pharmaceuticals Limited→ co mention →Chinese National Medical Products Administration51 evidence records
- Chinese National Medical Products Administration→ co mention →European Union46 evidence records
- American Society Of Pediatric Hematology Oncology→ co mention →Chinese National Medical Products Administration45 evidence records
- Chinese National Medical Products Administration→ co mention →Mint Incorporation Limited Mint39 evidence records
- Company Annual Bonus Plan→ co mention →Chinese National Medical Products Administration39 evidence records
- Prnewswire Oracle Corporation→ co mention →Chinese National Medical Products Administration39 evidence records
- Chinese National Medical Products Administration→ co mention →Ariel Guarco39 evidence records
- Pfizer→ co mention →Chinese National Medical Products Administration37 evidence records
- Health Canada Red Tape→ co mention →Chinese National Medical Products Administration36 evidence records
- Facebook→ co mention →Chinese National Medical Products Administration36 evidence records
- Corporate Communications Department→ co mention →Chinese National Medical Products Administration36 evidence records
- Energy In Asia Pacific→ co mention →Chinese National Medical Products Administration36 evidence records
- Chinese Academy Of Sciences→ co mention →Chinese National Medical Products Administration35 evidence records
- European Commission On Russian→ co mention →Chinese National Medical Products Administration35 evidence records
- Astrazeneca→ co mention →Chinese National Medical Products Administration32 evidence records
- Society For Tropical Ecology→ co mention →Chinese National Medical Products Administration29 evidence records
- Chinese National Medical Products Administration→ co mention →Eli Lilly27 evidence records
- University Hospitals Seidman Cancer Center→ co mention →Chinese National Medical Products Administration27 evidence records
- Yifang Zhu→ co mention →Chinese National Medical Products Administration24 evidence records
- Lupin Manufacturing Solutions→ co mention →Chinese National Medical Products Administration23 evidence records
- European Medicines Agency Clinical Trial Application→ co mention →Chinese National Medical Products Administration22 evidence records
- Iranian Customs Administration→ co mention →Chinese National Medical Products Administration21 evidence records
- Chinese National Medical Products Administration→ co mention →China Emergency Management Ministry On Monday21 evidence records
- Peter Ajemian→ co mention →Chinese National Medical Products Administration21 evidence records
- Amarillo Biosciences→ co mention →Chinese National Medical Products Administration21 evidence records
- Australian Stock Exchange On→ co mention →Chinese National Medical Products Administration20 evidence records
- Christian Behrenbruch→ co mention →Chinese National Medical Products Administration20 evidence records
- International Law→ co mention →Chinese National Medical Products Administration20 evidence records
- Chinese National Medical Products Administration→ co mention →Armen Kasparian20 evidence records
- Jay Melder→ co mention →Chinese National Medical Products Administration20 evidence records
- Chinese National Medical Products Administration→ co mention →Dana-Farber Cancer Institute19 evidence records
Ask this desk
Desk analyst
Read-only questions about Chinese National Medical Products Administration's stored record. Answers cite only records retrieved for that turn; a citation chip opens the existing inspection view. Absence of matches is not evidence of inactivity.
Operator sign-in is required. Sign in